Latest / Stock Movers / GSK Jumps, Astrazeneca Up
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios. Podcasts. Radio.
- 0:06Speaker 2: News.
- 0:08Speaker 1: The Stock Movers Report. Your roundup of companies making moves
- 0:12Speaker 1: in the stock market. Harnessing the power of Bloomberg data.
- 0:16Speaker 1: Let's take a look at some stocks on the move
- 0:17Speaker 1: today in Europe. I'm Stephen Cowell with Caroline Hepker and
- 0:20Speaker 1: we're joined by Bloomberg reporter Tiwa Adebayo. Tiwa, let's start
- 0:23Speaker 1: with pharma and a jump in GSK shares.
- 0:26Speaker 2: Yes, we've seen GSK shares rising about as much as 2.8%
- 0:29Speaker 2: this morning. And that's all got to do with some
- 0:32Speaker 2: positive data that is recorded from recent drug trials. So,
- 0:37Speaker 2: it's reported positive data in a mid-stage trial for a
- 0:40Speaker 2: drug for non-small cell lung cancer. That drug is called Judatro.
- 0:46Speaker 2: In terms of those results, GSK has announced that this
- 0:50Speaker 2: drug has achieved a 94% objective response rate in terms
- 0:56Speaker 2: of patients with no placebo comparator, and they are planning
- 1:01Speaker 2: a supplemental new drug application to the FDA this year
- 1:05Speaker 2: for that drug. They've also had some good news in
- 1:08Speaker 2: terms of their partner, Hanso Pharmaceutical. They've said that a
- 1:12Speaker 2: late-stage trial of another medicine has helped to reduce the
- 1:16Speaker 2: risk of death by 54% in Chinese patients. with a
- 1:21Speaker 2: type of small cell lung cancer too. So, some positive
- 1:25Speaker 2: news there for GSK in terms of new drug trials
- 1:28Speaker 2: that is driving their shares up this morning. Meanwhile, there's
- 1:31Speaker 2: also some news from GSK's rival AstraZeneca. Yeah, this is
- 1:35Speaker 2: an interesting one, Caroline. We're seeing AstraZeneca moving upwards just
- 1:40Speaker 2: under 2% so far this morning. But I do think
- 1:43Speaker 2: this is one to watch because they've actually had some
- 1:45Speaker 2: bad news So we heard on Friday that a recent
- 1:51Speaker 2: breast cancer pill trial has failed and it could cut
- 1:54Speaker 2: several billion dollars from the drug's potential sales. That's according
- 1:58Speaker 2: to analysts. So the drug failed to delay the disease
- 2:01Speaker 2: progression more than the standard treatment in a late stage situation.
- 2:05Speaker 2: study uh as i mentioned shares slightly up this morning
- 2:09Speaker 2: but bloomberg intelligence analysts saying this failure could reduce 2035
- 2:14Speaker 2: sales by between 2.6 billion dollars and 3.8 billion dollars
- 2:19Speaker 2: so the shares up so far but definitely something to
- 2:22Speaker 2: watch as analysts get to grips with that news later
- 2:26Speaker 2: on this morning.
- 2:28Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 2:33Speaker 1: us throughout the day for the latest roundup of companies
- 2:35Speaker 1: making news on Wall Street. And for the latest market-moving headlines,
- 2:39Speaker 1: listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com,
- 2:44Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 2:47Speaker 1: Business app.